Suppose that a unit of the Food and Drug Administration (FDA) is responsible for subsidizing pharmaceutical companies to develop new drugs for treating certain difficult cancers. Because of the expense, most drug companies are reluctant to take on this work, and the few that do complain that it is more expensive than they anticipated given all the safety regulations they must follow. In response, the FDA decides to waive certain safety trials so that the remaining companies do not drop out of the initiative. The FDA's decision has the desired effect: most of the companies stay in the program. However, six months after the new drugs are released, they are found to have serious side effects, side effects that typically would have been noticed during some of the safety trials. What term describes the FDA's behavior in this situation